Trial reportNature communications2022
Effect of biannual azithromycin distribution on antibody responses to malaria, bacterial, and protozoan pathogens in Niger.
Trial report in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02048007 (Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Morbidity Study
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Significant Predictors of Azithromycin in Population Pharmacokinetic Analysis: A Systematic Review.Drug design, development and therapy · 2025Pooled it
- Spillover of Azithromycin Mass Drug Administration and Child Survival: A Secondary Analysis of a Cluster-Randomized Clinical Trial.JAMA network open · 2025Trial
- Costs, Coverage, and Acceptability of Azithromycin Mass Administration to Children 1-11 Versus 1-59 Months Old to Reduce Mortality: A Cluster-Randomized Trial in Niger.The American journal of tropical medicine and hygiene · 2025Trial
- Effect of biannual azithromycin on respiratory pathogens among symptomatic children: results from the randomised Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) I trial.BMJ global health · 2025Trial
- Distance to Health Centers and Effectiveness of Azithromycin Mass Administration for Children in Niger: A Secondary Analysis of the MORDOR Cluster Randomized Trial.JAMA network open · 2023Trial
- Reconstructing pathogen-specific antibody binding epitopes and age-dependent immune signatures from proteomic-scale peptide libraries.Science advances · 2026Article
- Sources and transmission dynamics ofmedRxiv : the preprint server for health sciences · 2026Article
- Article
- Azithromycin mass drug administration to reduce childhood mortality in humanitarian crises.PLOS global public health · 2026Review
- Reconstructing pathogen-specific antibody binding epitopes and age-dependent immune signatures from proteomic-scale peptide libraries.medRxiv : the preprint server for health sciences · 2025Article
- Mass drug administration trials of azithromycin: an analysis to inform future research and guidelines.Infectious diseases of poverty · 2025Review
- Integrated Serosurveillance of Infectious Diseases Using Multiplex Bead Assays: A Systematic Review.Tropical medicine and infectious disease · 2025Review
- Challenges and Approaches to Establishing Multi-Pathogen Serosurveillance: Findings from the 2023 Serosurveillance Summit.The American journal of tropical medicine and hygiene · 2024Article
- Acquisition and clearance dynamics of Campylobacter spp. in children in low- and middle-income countries.Epidemics · 2024Article
- Comprehensive Profile of Pathogens and Antimicrobial Resistance in Conjunctivitis Cases from Niger.The American journal of tropical medicine and hygiene · 2023Article
- Monitoring transmission intensity of trachoma with serology.Nature communications · 2023Article
- Monitoring transmission intensity of trachoma with serology.medRxiv : the preprint server for health sciences · 2023Article
- Non-falciparum malaria infection and IgG seroprevalence among children under 15 years in Nigeria, 2018.Nature communications · 2023Article
- Dynamics of IgG antibody response againstFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
The MORDOR trial in Niger, Malawi, and Tanzania found that biannual mass distribution of azithromycin to children younger than 5 years led to a 13.5% reduction in all-cause mortality (NCT02048007). To help elucidate the mechanism for mortality reduction, we report IgG responses to 11 malaria, bacterial, and protozoan pathogens using a multiplex bead assay in pre-specified substudy of 30 communities in the rural Niger placebo-controlled trial over a three-year period (n = 5642 blood specimens, n = 3814 children ages 1-59 months). Mass azithromycin reduces Campylobacter spp. force of infection by 29% (hazard ratio = 0.71, 95% CI: 0.56, 0.89; P = 0.004) but serological measures show no significant differences between groups for other pathogens against a backdrop of high transmission. Results align with a recent microbiome study in the communities. Given significant sequelae of Campylobacter infection among preschool aged children, our results support an important mechanism through which biannual mass distribution of azithromycin likely reduces mortality in Niger.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.